Insmed, Inc. (NASDAQ:INSM) Receives Average Rating of “Moderate Buy” from Analysts

Insmed, Inc. (NASDAQ:INSM) has been given a consensus recommendation of “Moderate Buy” by the twenty-one brokerages that are covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, one has given a hold recommendation and nineteen have given a buy recommendation to the company. The average 1 year price objective among analysts that have covered the stock in the last year is $149.0625.

A number of equities analysts have recently weighed in on INSM shares. Mizuho increased their price target on Insmed from $130.00 to $165.00 and gave the stock an “outperform” rating in a report on Wednesday, August 13th. Stifel Nicolaus increased their price target on Insmed from $121.00 to $145.00 and gave the stock a “buy” rating in a report on Thursday, August 14th. HC Wainwright increased their price target on Insmed from $90.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, June 11th. Royal Bank Of Canada increased their price target on Insmed from $108.00 to $120.00 and gave the stock an “outperform” rating in a report on Friday, August 8th. Finally, Wells Fargo & Company increased their price target on Insmed from $140.00 to $171.00 and gave the stock an “overweight” rating in a report on Wednesday, September 3rd.

Insmed Stock Down 0.3%

NASDAQ INSM opened at $161.81 on Thursday. The business has a fifty day moving average price of $135.87 and a 200 day moving average price of $100.65. Insmed has a one year low of $60.40 and a one year high of $163.22. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68. The company has a market cap of $34.20 billion, a P/E ratio of -28.34 and a beta of 1.03.

Insmed (NASDAQ:INSM) last posted its quarterly earnings data on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The firm had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. During the same period in the prior year, the company posted ($1.94) earnings per share. The firm’s revenue for the quarter was up 18.9% compared to the same quarter last year. Insmed has set its FY 2025 guidance at EPS. Research analysts anticipate that Insmed will post -4.56 EPS for the current fiscal year.

Insider Activity at Insmed

In other news, COO Roger Adsett sold 25,000 shares of Insmed stock in a transaction dated Tuesday, August 19th. The stock was sold at an average price of $127.58, for a total value of $3,189,500.00. Following the completion of the transaction, the chief operating officer owned 105,637 shares in the company, valued at approximately $13,477,168.46. This trade represents a 19.14% decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, Director Melvin Md Sharoky sold 10,000 shares of Insmed stock in a transaction dated Friday, September 12th. The shares were sold at an average price of $145.39, for a total value of $1,453,900.00. Following the completion of the transaction, the director owned 262,675 shares of the company’s stock, valued at $38,190,318.25. The trade was a 3.67% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 219,568 shares of company stock worth $28,305,070 over the last ninety days. Company insiders own 3.00% of the company’s stock.

Institutional Investors Weigh In On Insmed

Several hedge funds and other institutional investors have recently made changes to their positions in INSM. Cullen Frost Bankers Inc. increased its position in Insmed by 164.9% during the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company’s stock worth $27,000 after buying an additional 221 shares during the period. ORG Partners LLC increased its position in Insmed by 220.2% during the second quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company’s stock worth $28,000 after buying an additional 196 shares during the period. Hilltop National Bank acquired a new position in Insmed during the second quarter worth approximately $28,000. FNY Investment Advisers LLC acquired a new position in Insmed during the second quarter worth approximately $33,000. Finally, NBC Securities Inc. acquired a new position in Insmed during the first quarter worth approximately $49,000.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed’s first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.